Can Inocras’ whole-genome HRD data change how ovarian cancer patients are selected for PARP maintenance?
PARP selection still leaves gaps. Inocras’ WGS-HRD data suggest whole-genome testing may refine ovarian cancer maintenance decisions.
What Epitopea’s MHRA-approved OVACT trial signals for off-the-shelf cancer vaccines
Find out how Epitopea’s CryptiVax-1001 trial could reshape RNA cancer vaccines and ovarian cancer treatment strategies.
Can Volastra Therapeutics turn KIF18A inhibition into a pan-cancer precision oncology platform?
Volastra Therapeutics unveils AACR 2026 biomarker and combination data for KIF18A inhibitors. Read what this means for oncology development.
AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
Read how SAGA Diagnostics’ AACR 2026 Pathlight data could reshape ctDNA monitoring in metastatic breast and ovarian cancer.
What Accent Therapeutics’ AACR 2026 ATX-295 update reveals about the next wave of precision oncology targets
Accent Therapeutics is expanding the ATX-295 story in solid tumors. Read what the new AACR 2026 data could change and what risks remain.